Promoting research partnerships to improve veterans’ health

NAVREF is proud to recognize Cohen Veterans Bioscience as our Champion Sponsor

NAVREF News Center

  • 4 May 2018 10:00 AM | Anonymous member (Administrator)

    FY18 LCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov. 

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

     

    Applications submitted to the FY18 LCRP must address at least one of the eight Areas of Emphasis listed below:

     

    • Identify, develop, or optimize noninvasive or minimally invasive tools to improve the detection of the initial stages of lung cancer, such as, but not limited to, optimizing strategies for management of indeterminate nodules.

    ·         Identify, develop, and/or build upon already existing tools for screening or early detection of lung cancer. Screening may include, but is not limited to, imaging modalities, biomarkers, genetics/genomics/proteomics/metabolomics/transcriptomics, and assessment of risk factors.

    ·         Understand the molecular mechanisms of initiation and progression to clinically significant lung cancer.

    ·         Identify innovative strategies for prevention and treatment of lung cancer.

    ·         Understand predictive markers to identify responders and nonresponders.

    ·         Understand mechanisms of resistance to treatment (primary and secondary).

    ·         Understand contributors to lung cancer development other than tobacco.

    ·         Identify innovative strategies for lung cancer care delivery (clinical management/ surveillance/symptom management).

    http://cdmrp.army.mil/funding/lcrp

    Concept Award – Letter of Intent due July 26, 2018

    ·         All investigators at or above the level of postdoctoral fellow (or equivalent)

    ·         Supports highly innovative, untested, potentially groundbreaking concepts in lung cancer

    • Emphasis on innovation
    • Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.101(b) or be eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.
    • Clinical trials not allowed

    ·         Preliminary data discouraged (not consistent with intent of award mechanism)

    ·         Military relevance strongly encouraged

    • Maximum funding of $100,000 in direct costs (plus indirect costs)

    ·         Period of performance should not exceed 1 year

     

    Career Development Award – Letter of Intent due September 6, 2018

    ·         Principal Investigator:  Independent investigators at the level of Assistant Professor, Instructor, or equivalent; must be within 5 years of first faculty appointment

    ·         Must not have received a Career Development Award previously from any program within the Congressionally Directed Medical Research Programs.

    ·         Must not have received more than $300,000 in total direct costs for previous or concurrent lung cancer research as a PI of one of more federally or privately funded, non-mentored, peer-reviewed grants

    ·         Mentor:  At or above the level of Associate Professor (or equivalent);

    ·         Must have a  strong publication and funding record in lung cancer research

    ·         Supports early-career, independent researchers to conduct research under mentorship of an experienced lung cancer researcher

    ·         Clinical trials not allowed

    ·         Preliminary data not required

    ·         Military relevance strongly encouraged

    ·         Maximum funding of $250,000 in direct costs (plus indirect costs)

    ·         Period of performance should not exceed 2 years

     

    Idea Development Award – Preproposal due June 26, 2018

    • Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent); or
    • New Investigators:  Investigators that meet the following criteria at the application submission deadline date:

    o   Have not previously received a LCRP Idea Development Award or Early Investigator Synergistic Idea Award

    o   Be within 10 years of first faculty appointment (or equivalent)

    • Supports new ideas in the early stages of development representing innovative, high-risk/high-gain research
    • Emphasis on innovation and impact
    • New Investigators: Supports applicants early in their faculty appointments or in the process of developing independent research careers
    • Clinical trials not allowed
    • Preliminary data required, but may be from outside of lung cancer

    ·         Military relevance strongly encouraged

    ·         Maximum funding of $350,000 in direct costs (plus indirect costs)

    ·         Period of performance should not exceed 2 years

     

    Investigator-Initiated Translational Research Award – Preproposal due June 26, 2018

    • Independent investigators at or above the level of Assistant Professor (or equivalent)
    • Supports translational research that will develop promising ideas in lung cancer into clinical applications.  Translational research may be defined as an integration of basic science and clinical observations
    • Intended to fund a broad range of translational studies.
    • Clinical trials not allowed.
    • Preliminary Date required, but may be from outside of lung cancer.
    • Military relevance strongly encouraged.

    ·         Maximum funding of $400,000 in direct costs (plus indirect costs)

    • Period of performance should not exceed 2 years

     

    Translational Research Partnership Award – Preproposal due June 26, 2018

    • Investigators at or above the level of Assistant Professor (or equivalent)
    • Supports partnerships between clinicians and laboratory scientists that accelerate ideas in lung cancer into clinical applications
    • One partner is strongly encouraged to be from a Department of Defense military treatment facility or laboratory, or Veterans Affairs medical center or research laboratory.
    • Non-Traditional Partnerships are encouraged.
    • Clinical trials are allowed.
    • Preliminary data required, but may be from outside of lung cancer
    • Maximum combined funding of $900,000 in direct costs (plus indirect costs)
    • Maximum period of performance is 3 years
    • Military relevance strongly encouraged

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that are available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Applications must be submitted through the federal government’s single-entry portal, Grants.govFor email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the LCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk
    301-682-5507
    help@eBrap.org


  • 1 May 2018 2:46 PM | Anonymous member (Administrator)

    FY18 BMFRP Program Announcement and General Application Instructions for the following award mechanism are posted on Grants.gov.

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    http://cdmrp.army.mil/funding/bmfrp

    Idea Development Award – Preproposal due July 16, 2018

    Established Investigators:
    Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from a terminal degree
    or
    Early-Career Investigators:
    Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or on family medical leave) at the time of application submission deadline are eligible.

    • Preapplication is required; application submission is by invitation only.
    • Supports innovative ideas and high-impact approaches based on scientifically sound evidence in order to move toward the vision to understand and cure bone marrow failure (BMF).
    • Strong BMF research team.
    • May include relevant preliminary data.
    • Maximum funding of $325,000 in direct costs (plus indirect costs)
    • Period of performance not to exceed 2 years
    • Clinical trials will not be supported.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcement and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov website. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov website. For email notification when the Program Announcement is released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the BMFRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk

    301-682-5507
    help@eBRap.org


  • 27 Apr 2018 8:23 AM | Anonymous member (Administrator)

    The FY18 Defense Appropriation provides $15 million (M) to the Department of Defense Vision Research Program (VRP) to support innovative, high-impact vision research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The VRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY18 VRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in July 2018.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    http://cdmrp.army.mil/pubs/press/2018/18vrppreann

    Focused Translational Team Science Award (FTTSA)

    PIs must be independent investigators at or above the level of Associate Professor (or equivalent) with experience in developing and running large-scale initiatives.

    • Co-investigators may be independent investigators at all academic levels (or equivalent).
    • Preproposal is required; application submission is by invitation only.
    • Support highly collaborative and translational team initiatives that would fundamentally advance the understanding and treatment of vision trauma. 
    • Must focus on eye injury or visual dysfunction as related to a traumatic event.  Examples of trauma include, but are not limited to:
    • Blast, blunt, thermal or chemical trauma;
    • Trauma caused by directed energy weapons such as laser, microwaves and particle beams;
    • Ionizing radiation
    • Must be a multifaceted, multidisciplinary and highly coherent investigation with 3-5 teams addressing complementary and synergistic questions that center around a specific trauma.  Examples of questions include, but are not limited to:
    • Elucidation of molecular, cellular, and biophysical mechanisms;
    • Identification of biomarkers and potential therapeutic targets;
    • Development and validation of therapeutic agents and/or devices;
    • Development and validation of drug delivery platforms appropriate for said trauma;
    • Development or improvement of clinically relevant models for said trauma;
    • Design of protection to mitigate the impact of said trauma on eye and vision.
    • The proposal should spell out the goals of individual teams as well as describe the ways for the teams to cooperate and effectively share and utilize the newly acquired knowledge in moving the project forward.
    • Preliminary data required.
    • Clinical trials are not allowed
    • Will be funded by Cooperative Agreement.
    • Emphasis is on synergy, translational potential, and strategy to transition findings into products.
    • Maximum funding of $5,000,000 for direct costs (plus indirect costs)
    • Maximum period of performance is year

    Investigator Initiated Research Award (IIRA)

    • Independent investigators at all academic levels (or equivalent).
    • Preproposal is required; application submission is by invitation only.
    • Must focus on eye injury or visual dysfunction as related to a traumatic event.  Examples of trauma include, but are not limited to:
      • Blast, blunt, thermal or chemical trauma;
      • Trauma caused by directed energy weapons such as laser, microwaves and particle beams;
      • Ionizing radiation
    • Preliminary data required.
    • Clinical trials are not allowed.
    • Emphasis is on impact and innovation.
    • Maximum funding of $500K for direct costs (plus indirect costs)
    • Maximum period of performance is 3 years

    Expansion Award (EA)

    • Current Principal Investigator (PI) of VRP awards that were initiated in FY13, FY14, or FY15
    • Each PI is eligible to submit one application per previous award received.
    • Preproposal is required; both preproposal submission and full application submission are by invitation only.
    • Support the continued investigation and further development of highly impactful VRP-funded projects that were initiated in FY13, FY14, or FY15.
    • Applications must include an Outcomes Statement that briefly details the research funded through the initial VRP award and describes the results, accomplishments, and outcomes from that award.  PIs should explain how these results, accomplishments, and outcomes relate to the proposed research and describe how expansion of the original research results would impact vision research and patient care.
    • Preliminary data required.
    • May support preclinical studies that involve cell lines and/or animal models, clinical studies involving human subjects and/or human anatomical substances, or pilot clinical trials that collect preliminary data to support the rationale and design of subsequent clinical trials.
    • Emphasis is on translational potential and impact.
    • Maximum funding of $500K for direct costs (plus indirect costs)
    • Maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the VRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 17 Apr 2018 3:07 PM | Anonymous member (Administrator)

    The FY18 Defense Appropriation provides $30 million (M) to the Department of Defense Spinal Cord Injury Research Program (SCIRP) to support innovative, high-impact spinal cord injury research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The SCIRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY18 SCIRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in May 2018.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    For FY18, SCIRP encourages applications that address the critical needs of SCI research and patient care in one or more of the following FY18 Focus Areas:

    • Neuroprotection
    • Biomarkers
    • Bladder and bowel dysfunction and neuropathic pain
    • Psychosocial issues relevant to SCI in  individuals with SCI and their caregivers
    • Rehabilitation and regeneration

    http://cdmrp.army.mil/pubs/press/2018/18scirppreann

    Clinical Trial Award

    Independent investigators at all academic levels (or equivalent)

    • Preproposal is required; application submission is by invitation only.
    • Fund Phase 0, I, or II clinical trials with the potential to have a major impact on treatment or management of spinal cord injury (SCI) and its consequences.
    • Preclinical data required for all clinical trial applications.
    • Maximum funding of $3M for direct costs (plus indirect costs)
    • Maximum period of performance is years

    Investigator-Initiated Research Award

    Independent investigators at all academic levels (or equivalent)

    • Preproposal is required; application submission is by invitation only.
    • Fund SCI-related research that has the potential to make an important contribution to SCI research and/or patient care.
    • Preliminary data required.
    • Clinical trials not allowed.
    • Maximum funding of $500,000 for direct costs (plus indirect costs)
    • Maximum period of performance is 3 years.

    Qualitative Research Award

    Independent investigators at all academic levels (or equivalent)

    • Preproposal is required; application submission is by invitation only.
    • Fund qualitative research on military Service members and Veterans in the years following SCI.
    • Qualitative research is defined as a form of social inquiry that focuses on understanding the way that people interpret and make sense of their experiences and the world in which they live (i.e., seek to understand the human experience).
    • Preliminary data encouraged, but not required.
    • Clinical trials not allowed.
    • Maximum funding of $500,000 for direct costs (plus indirect costs)
    • Maximum period of performance is 3 years

    Translational Research Award

    Independent investigators at all academic levels (or equivalent)

    • Preproposal is required; application submission is by invitation only.
    • Fund studies that accelerate the movement of promising ideas in SCI research into clinical applications.
    • Preliminary data required
    • The SCIRP TRA may include a pilot clinical trial as part of the proposed research where limited clinical testing of a novel intervention or device is necessary to inform the next step in the continuum of translational research.
    • Maximum funding of $1.25M for direct costs (plus indirect costs)
    • Maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the SCIRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 17 Apr 2018 9:17 AM | Anonymous member (Administrator)

    FY18 ALSRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    The mission of the ALSRP is to fund innovative pre-clinical research to develop new treatments for ALS for the benefit of Service members, Veterans, and the general public.

    http://cdmrp.army.mil/funding/alsrp

    The following mechanisms are planned for release:

    Therapeutic Development Award – Preproposal due June 22, 2018

    • Independent investigators at all academic levels
    • Pre-application is required; full application submission is by invitation only
    • Supports post-discovery, preclinical development of therapeutics for ALS
    • Preliminary data, including identify and purity of an identified bioactive compound(s), are required
    • Types of efforts that will be supported include:
      • Confirmation of candidate therapeutics obtained from screening or by other means
      • Validation of early pilot studies in multiple model systems and/or replicating preliminary data with more time points or additional doses
      • Optimization of potency and pharmacology, studies of formulation, stability and production methods based on Good Manufacturing Practices
      • Investigational New Drug (IND)-enabling studies
    • Clinical trials are not allowed
    • Collaboration with industry is encouraged
    • Does not support screening or development of screens or models
    • New! The following option, with additional funding for qualified applications, is being offered:
    • Therapeutic Relevance Option supports development of markers that will improve the drug development process in parallel with the main therapeutic advancement effort.
    • Applicants must submit a Therapeutic Relevance Statement that clearly describes how the marker is quantifiable and has potential to improve the efficacy of the therapy development process.
    • Application to this option is not a requirement for TDA submission
    • A TDA application requesting the higher level of funding that does not meet the specified criteria may be funded at the lower level
    • Standard award maximum funding of $1,000,000 for direct costs
    • Standard award with Option:
      • If applying for the Therapeutic Relevance Option, maximum funding of up to $1,250,000 for direct costs
    • Maximum period of performance is 2 years
    • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

     

    Therapeutic Idea Award – Preproposal due June 22, 2018

    • Independent investigators at all academic levels
    • Pre-application is required; full application submission is by invitation only.
    • Supports new ideas aimed at drug or treatment discovery that are still in the early stages of development
    • Preliminary data are not required
    • Types of efforts that will be supported include:

    o    Exploitation of pathways known to be relevant to ALS for the purpose of improving treatment and/or advancing a novel treatment modality

    o    Development, modification, and use of high-throughput screens and novel model systems to define or assess lead compounds

    o    Projects that focus primarily on investigating the pathophysiology of ALS are outside of the scope of this announcement

    • Maximum funding of $500,000 for direct costs
    • Maximum period of performance is 2 years
    • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the ALSRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk
    301-682-5507
    help@eBrap.org


  • 5 Apr 2018 2:29 PM | Anonymous member (Administrator)

    The FY18 Defense Appropriations Act provides $6 million (M) to the Department of Defense Tuberous Sclerosis Complex Research Program (TSCRP) to support innovative, high-impact TSC research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    The TSCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY18 TSCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in May 2018.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    Focus Areas:  The goal of the FY18 TSCRP is to fund exploratory, pioneering and transformative science that promotes discoveries in TSC, from mechanistic insights to clinical application, by supporting new ideas and investigators for the benefit of Service members, their beneficiaries, and the American public.  Within this context, the FY18 TSCRP encourages applications that address the critical needs of the TSC community in one or more of the following FY18 Focus Areas:

    ·        Gaining a deeper knowledge of TSC signaling pathways and the cellular consequences of TSC deficiency

    ·        Improving TSC disease models

    ·        Examining the clinical aspects of TSC, including phenotypic heterogeneity

    ·        Facilitating therapeutics, biomarkers, and clinical trials research

    http://cdmrp.army.mil/pubs/press/2018/18tscrppreann

    Exploration - Hypothesis Development Award

    • Investigators at all academic levels (or equivalent), including postdoctoral fellows
    • Supports the initial exploration of innovative, high-risk, high gain, and potentially groundbreaking concepts in the TSC research field.
    • Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.101(b)(4) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.
    • Preliminary data are not required.
    • Research projects must be innovative, feasible, and supported by a strong rationale.
    • Clinical trials are not allowed.
    • Maximum funding of $100,000 for direct costs (plus indirect costs)
    • Maximum period of performance is year

    Idea Development Award

    • Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent);
    • or
    • New Investigators:  
    • Independent investigator at or below the level of Assistant Professor (or equivalent); or
    • Established independent investigator in an area other than TSC at or above the level of Assistant Professor seeking to transition to a career in TSC thereby bringing his/her expertise to the field.
    • Must not have received more than $300,000 in total direct costs for previous or concurrent TSC research as a PI of one or more Federally funded, non-mentored peer-reviewed grants. (National Institutes of Health K/R00 Awardees are eligible to apply.)
    • Must not have received a New Investigator Award previously from any program within the CDMRP.
    • Supports new ideas that have the potential to yield high-impact findings and new avenues of investigation.
    • Preliminary data are expected.
    • Clinical trials are not allowed.
    • New Investigator Option supports the continued development of promising independent investigators and/or the transition of established investigators from other research fields into a career in TSC research.
    • Applications from New Investigators and Established Investigators will be peer- and programmatically reviewed separately.
    • Maximum funding of $450,000 for direct costs (plus indirect costs)
    • Maximum period of performance is 3 years

    Clinical Translational Research Award

    • Independent investigators at or above the level of Assistant Professor (or equivalent)
    • Supports forward or reverse clinical/translational research studies.
    • Preference will be given to studies that involve human samples, patients, or leverage existing clinical data and/or ongoing clinical studies. 
    • Preclinical studies may be appropriate but must include a clinical component.
    • Applications may include a small, pilot clinical trial intended to inform the next step in the continuum of translational research.
    • Preliminary data are required
    • Maximum funding of $600,000 for direct costs (plus indirect costs)
    • Maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the TSCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 2 Apr 2018 2:31 PM | Anonymous member (Administrator)

    The FY18 Defense Appropriations Act provides $15 million (M) to the Department of Defense Peer Reviewed Alzheimer’s Research Program (PRARP) to support research which addresses the long-term consequences of traumatic brain injury (TBI) as they pertain to Alzheimer’s disease (AD) and related dementias (ADRD).  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    The PRARP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY18 PRARP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in May 2018.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    FY18 PRARP Overarching Challenges and Focus Areas:

    All applications for FY18 PRARP funding opportunities must address at least one of the following FY18 Overarching Challenges.  The FY18 Overarching Challenges may be mechanism-specific. 

    FY18 PRARP Overarching Challenges are listed below.

    PRARP FY18 Overarching Challenges

    Paucity of Research Resources:  The paucity of research resources to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities.

    Paucity of Clinical Studies:  The paucity of clinical studies to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities.  This includes research into risk factors which may predispose individuals to AD/ADRD subsequent to TBI.

    Diagnostic Technologies, Tests, Biomarkers, or Devices:  The need for technologies, tests, or devices to detect or prognose the progression to AD/ADRD subsequent to TBI.  This includes research into risk factors which may predispose individuals to AD/ADRD subsequent to TBI.

    Quality of Life:  The need for technologies, assessments, interventions, or devices to benefit individuals living with the common symptoms or deficits of TBI and AD/ADRD.

    Caregiver Support:  The need for technologies, assessments, interventions, or devices with the goal of enhancing the lives of caregivers for individuals living with the common symptoms or deficits of TBI and AD/ADRD.

    Epidemiology:  The paucity of epidemiological research to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities.  This includes research into risk factors which may predispose individuals to AD/ADRD subsequent to TBI.

    In addition to addressing one or more of the specified FY18 Overarching Challenges, applications should also address at least one of the following FY18 Focus Areas in support of the FY18 Overarching Challenges.  An application that proposes research outside of the FY18 Focus Areas is acceptable, as long as the applicant provides a strong rationale.  The Focus Areas will be mechanism-specific.

    The PRARP FY18 Focus Areas are listed below.

    PRARP FY18 Focus Areas

    Mechanisms of Pathogenesis:  Identification of contributing mechanisms (e.g., diffuse/traumatic axonal injury, roles of non-neuronal cells, neuroinflammation, immune regulation, biology/pathology of tau, vascular contributions, and omics techniques for examining mechanisms) associated with TBI and subsequent AD/ADRD pathogenesis.

    Biomarkers:  Development of strategies to diagnose, prognose, or characterize neurological changes or risk factors associated with TBI and subsequent AD/ADRD (e.g., fluid based, imaging-based, physiological, and omics techniques for biomarkers).

    Quality of Life:  Research intended to alleviate, stabilize, or characterize the symptoms, or deficits, common to TBI, AD, and ADRD.  Examples of research in this Focus Area include:  Identification and management of comorbidities and modifiable risk factors (e.g., sleep apnea, obesity), cognitive training interventions, studies of health and wellness, and behavioral interventions.

    Caregiver Support:  Research intended to enhance the role of the caregiver for individuals living with the common symptoms or deficits of TBI and AD/ADRD.  Examples of research in this Focus Area include:  Caregiver training, home-based support, behavioral interventions, and relationship interventions.

    Epidemiological Research:  Research focusing on the incidence, distribution, and other factors relating to the health of individuals affected by TBI and subsequent AD/ADRD.

    Novel Target Identification:  Basic research (non-human) directly leading to the identification of new targets for the development of existing or new investigational medicines, drugs, or agents.

    Nonpharmacological Interventions:  Research into non-medication-based interventions to improve quality of life or caregiving for those living with AD/ADRD.

    The following is a summary of the FY18 PRARP Program Announcements.  Four award mechanisms will be offered for FY18.  This pre-announcement should not be construed as an obligation by the Government.

    http://cdmrp.army.mil/pubs/press/2018/18prarppreann

    Convergence Science Research Award

    Principal Investigators (PIs) at or above the level of Assistant Professor (or equivalent).

    Intent:  Support efforts to generate research resources, tools, or novel research efforts for researchers and/or practitioners in health sciences.

    Applications must address one or more of the following FY18 PRARP Overarching Challenges:

    ·        Paucity of Research Resources

    ·        Paucity of Clinical Studies

    ·        Diagnostic Technologies, Tests, Biomarkers, or Devices

    ·        Epidemiology

    Applications should address at least one of the following FY18 PRARP Focus Areas:

    ·        Mechanisms of Pathogenesis

    ·        Biomarkers

    ·        Epidemiological Research

    ·        Novel Target Identification

    Research considering pharmacologic interventions is specifically discouraged under this mechanism.

    Preliminary data, while not required, are encouraged.

    • Maximum funding is $500,000 for direct costs (plus indirect costs).
    • Maximum period of performance is 3 years.
    • Indirect costs may be proposed in accordance with the institution’s rate agreement.

    Quality of Life Research Award (QUAL)

    PIs at or above the level of Assistant Professor (or equivalent).

    Intent:  The intent of the QUAL mechanism is to support preclinical, basic, epidemiological, or quality-of-life research to alleviate or characterize the common symptoms of TBI and AD/ADRD.

    Applications must address one or more of the following FY18 PRARP Overarching Challenges:

    ·        Paucity of Clinical Studies

    ·        Epidemiology

    ·        Quality of Life

    ·        Caregiver Support

    Applications should address at least one of the following FY18 PRARP Focus Areas:

    ·        Biomarkers

    ·        Quality of Life

    ·        Caregiver Support

    ·        Nonpharmacological Interventions

    ·        Epidemiological Research

    Research considering pharmacologic interventions is specifically discouraged under this mechanism.

    Preliminary data, while not required, are encouraged.

    • Funding limit is $500,000 in direct costs.
    • Maximum period of performance is 3 years.
    • Indirect costs may be proposed in accordance with the institution’s rate agreement.

    New Investigator Award

    The PI must be an independent, early-career investigator within 3 years of his/her first independent faculty position (or equivalent).

    Intent:  Support early-career investigators interested in novel research efforts or new technologies within TBI and AD/ADRD.

    Applications must address one or more of the following FY18 PRARP Overarching Challenges:

    ·        Paucity of Research Resources

    ·        Paucity of Clinical Studies

    ·        Diagnostic Technologies, Tests, Biomarkers, or Devices

    ·        Epidemiology

    ·        Quality of Life

    ·        Caregiver Support

    Applications should address at least one of the following FY18 PRARP Focus Areas:

    ·        Mechanisms of Pathogenesis

    ·        Biomarkers

    ·        Quality of Life

    ·        Caregiver Support

    ·        Epidemiological Research

    ·        Novel Target Identification

    ·        Nonpharmacological Interventions

    Research considering pharmacologic interventions is specifically discouraged under this mechanism.

    Preliminary data, while not required, are encouraged.

    • Funding limit is $225,000 in direct costs.
    • Maximum period of performance is 3 years.
    • Indirect costs may be proposed in accordance with the institution’s rate agreement.

    Research Partnership Award

    The PI must be an independent investigator at or above the level of Assistant Professor (or equivalent).

    Intent:  To create an avenue for partnerships between investigators to address a research problem or question in a manner that would be unachievable through separate efforts.

    Applications must include clearly stated plans for interactions between the partners. The plans must include communication, coordination of research progress and results, and data sharing between all investigators and organizations participating in the project.

    Applications must address one or more of the following FY18 PRARP Overarching Challenges:

    ·        Paucity of Research Resources

    ·        Paucity of Clinical Studies

    ·        Diagnostic Technologies, Tests, Biomarkers, or Devices

    ·        Epidemiology

    ·        Quality of Life

    ·        Caregiver Support

    Applications should address at least one of the following FY18 PRARP Focus Areas:

    ·        Mechanisms of Pathogenesis

    ·        Biomarkers

    ·        Quality of Life

    ·        Caregiver Support

    ·        Epidemiological Research

    ·        Novel Target Identification

    ·        Nonpharmacological Interventions

    Research considering pharmacologic interventions is specifically discouraged under this mechanism.

    Preliminary data are required.

    ·        Funding limit is $1.3M in total costs.

    ·        Maximum period of performance is 3 years.

    ·        Indirect costs may be proposed in accordance with the institution’s rate agreement.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PRARP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 2 Apr 2018 2:21 PM | Anonymous member (Administrator)

    The FY18 Defense Appropriations Act provides $7.5 million (M) to the Department of Defense Epilepsy Research Program (ERP) to explore the causative links between traumatic brain injury (TBI) and epilepsy, with the hope that, one day, post-traumatic epilepsy (PTE) will be preventable.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    The ERP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY18 ERP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in May 2018.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the Government.

    Applications should also address at least one of the ERP FY18 Focus Areas.  An application that proposes research outside of the FY18 Focus Areas is acceptable, as long as the applicant provides a strong rationale.  The Focus Areas will be mechanism-specific.

    The ERP FY18 Focus Areas are as follows:

    Epidemiology:  Epidemiological characterization of PTE following TBI, which may include:

    • Risk factors such as demographics, genetic factors, organic head injury factors, or type of insult
    • Differentiation of PTE and Psychogenic Non-Epileptic Seizures (PNES)
    • Outcomes including latency to epilepsy, morbidities and comorbidities, and mortality
    • Pre-existing conditions including psychological and psychiatric risk factors
    • Treatment

    Markers and Mechanisms:  Identifying markers or mechanisms (via clinical prospective or preclinical models) that address PTE, which may include the following:

    • Early detection
    • Diagnosis
    • Prognosis
    • Morbidity
    • Comorbidity
    • Mortality
    • Risk stratification

    Note:  Research considering the development of new models or better characterization of existing etiologically relevant models for PTE, including repetitive TBI, could be considered under this Focus Area.

    Longitudinal Studies:  Studies of the natural evolution of PTE, which may include the following:

    • Seizure frequency and severity
    • Comorbidities (e.g., depression, functional deficits, sleep disorders, major illness)
    • Latency between injury and PTE
    • Mortality
    • Treatment
    • Quality of life of individuals with PTE

    Longitudinal Risk Factors Award

    The Principal Investigator must be an independent investigator at or above the level of Assistant Professor (or equivalent).  Investigators must have a patient cohort identified.

    Intent:  To facilitate high-impact, systematic, cohort-based research investigating the natural evolution of PTE from TBI.

    • Responsive to the Longitudinal Focus Area Only.
    • Preliminary data are required.
    • Must describe how the inter-relationship between TBI and PTE will be assessed or characterized.
    • Must describe the nature of the cohort (military, etc.)
    • Must describe the study outcomes to be captured.
    • Must describe the nature of the TBIs within the study cohort.
    • Requires a Biostatistician.
    • Applications that develop interdisciplinary teams or consortia as part of the support plan for executing the research are encouraged.
    • Research considering a pharmacologic intervention is specifically discouraged under this mechanism.
    • Maximum funding of $2,500,000 for direct costs (plus indirect costs).
    • Maximum period of performance is 4 years.
    • Indirect costs may be proposed in accordance with the institution's rate agreement.

    http://cdmrp.army.mil/pubs/press/2018/18erppreann

    Idea Development Award

    Level I:  The Principal Investigator must be at or above the level of postdoctoral fellow (or equivalent), but below the level of Assistant Professor (or equivalent).  

    Level II:  The Principal Investigator must be an independent investigator at or above the level of Assistant Professor (or equivalent).

    Intent:  To solicit research to understand the magnitude and underlying mechanisms of PTE, especially in Service members and Veterans, while also benefitting the civilian community. 

    ·      Level I is intended to support high-risk or high-gain research from researchers at or above the level of a post-doctoral fellow (or equivalent). 

    ·      Level II is intended to support a more mature, hypothesis-driven research project.

    The following Focus Areas are open to both Levels I and II:

    ·        Epidemiology

    ·        Markers and Mechanisms

    ·        Longitudinal Studies

    ·        Preliminary data, while not required, are encouraged for both levels.

    Research considering a pharmacologic intervention is specifically discouraged under this mechanism.

    Level I:

    ·      Maximum funding of $300,000 for direct costs (plus indirect costs).

    ·      Maximum period of performance is 2 years.

    ·      Indirect costs may be proposed in accordance with the institution's rate agreement.

    Level II:

    ·      Maximum funding of $500,000 for direct costs (plus indirect costs).

    ·      Maximum period of performance is 3 years.

    Indirect costs may be proposed in accordance with the institution's rate agreement.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Applications must be submitted through the Federal Government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the ERP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 28 Mar 2018 1:33 PM | Anonymous member (Administrator)

    The Fiscal Year 2018 Department of Defense Appropriations Act provides research funding for the following peer reviewed programs managed by the Department of Defense office of Congressionally Directed Medical Research Programs (CDMRP):

    • Alcohol and Substance Abuse Research Program - $4.0 million
    • Amyotrophic Lateral Sclerosis Research Program - $10 million
    • Autism Research Program - $7.5 million
    • Bone Marrow Failure Research Program - $3.0 million
    • Breast Cancer Research Program - $130.0 million
    • Duchenne Muscular Dystrophy Research Program - $3.2 million
    • Epilepsy Research Program - $7.5 million
    • Gulf War Illness Research Program - $21.0 million
    • Hearing Restoration Research Program - $10.0 million
    • Kidney Cancer Research Program - $15.0 million
    • Joint Warfighter Medical Research Program - $50.0 million
    • Lung Cancer Research Program - $14.0 million
    • Lupus Research Program - $5.0 million
    • Military Burn Research Program - $8.0 million
    • Multiple Sclerosis Research Program - $6.0 million
    • Neurofibromatosis Research Program - $15.0 million
    • Orthotics and Prosthetics Outcomes Research Program- $10.0 million
    • Ovarian Cancer Research Program - $20.0 million
    • Parkinson's Research Program - $16.0 million
    • Peer Reviewed Alzheimer's Research Program - $15.0 million
    • Peer Reviewed Cancer Research Program (17 Topics) - $80.0 million
    • Peer Reviewed Medical Research Program (52 Topics) - $330.0 million
    • Peer Reviewed Orthopaedic Research Program - $30.0 million
    • Prostate Cancer Research Program - $100.0 million
    • Reconstructive Transplant Research Program - $12.0 million
    • Spinal Cord Injury Research Program - $30.0 million
    • Tick-Borne Disease Research Program - $12.0 million
    • Trauma Clinical Research Program - $10 million
    • Tuberous Sclerosis Complex Research Program - $6.0 million
    • Vision Research Program - $15.0 million

    Comprehensive Program Announcements will be released during 2018. The Program Announcements will include detailed descriptions of funding mechanisms, evaluation criteria, submission requirements, and deadlines. Each Program Announcement may be downloaded from the Grants.gov website http://www.grants.gov, or the CDMRP website http://cdmrp.army.mil upon its release.

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at
    https://ebrap.org.

    For more information about the CDMRP, our research programs, previous awardees, as well as research highlights and videos, please visit the website at
    http://cdmrp.army.mil.

    Point of Contact:

    CDMRP Public Affairs
    301-619-7783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 28 Mar 2018 9:35 AM | Anonymous member (Administrator)

    FY18 BCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov. 

     

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

     

    Applications submitted to the FY18 BCRP must address one or more of the following overarching challenges:

    • ·         Prevent breast cancer (primary prevention)
    • ·         Identify determinants of breast cancer initiation, risk, or susceptibility
    • ·         Distinguish deadly from non-deadly breast cancers
    • ·         Conquer the problems of over diagnosis and overtreatment
    • ·         Identify what drives breast cancer growth; determine how to stop it
    • ·         Identify why some breast cancers become metastatic
    • ·         Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
    • ·         Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival
    • ·         Eliminate the mortality associated with metastatic breast cancer

     

    http://cdmrp.army.mil/funding/bcrp

     

    Breakthrough Award Level 1 & 2– Letter of Intent due May 16, 2018 for Level 1 & 2

    • ·         Investigators at all academic levels (or equivalent)
    • ·         Senior postdoctoral fellows who do not meet the eligibility requirements of the Breakthrough Fellowship Award are encouraged to apply under Funding Levels 1 and 2
    • ·         Each investigator may submit only one Funding Level 1 application and one Funding Level 2 application as a PI or Initiating PI.
    • ·         Supports promising research that has the potential to lead to or make breakthroughs in breast cancer.
    • ·         Potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement.
    • ·         Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application.
    • ·         It is the responsibility of the PI to select the funding level that is most appropriate for the research proposed.  The funding level should be selected based on the scope of the research project, rather than the amount of the budget.
    • ·         There are no limitations on the number of applications for which an investigator may be named as a
    • ·         Partnering PI.  However, applicants are discouraged from submitting as a Partnering PI on multiple applications unless they are clearly unique, meaningful collaborations addressing distinct research questions.
    • ·         Additional funds are available for applications submitted under the Partnering PI Option.
    • ·         Clinical trials are not allowed.
    • ·         Submission of a Letter of Intent is required prior to full application submission.
    • ·         Funding Level 1:
    • ·         Maximum funding of $375,000 for direct costs (plus indirect costs)
    • ·         Maximum period of performance is 3 years
    • ·         Funding Level 1 – Partnering PI Option:
    • ·         Maximum funding of $600,000 for direct costs (plus indirect costs)
    • ·         Maximum period of performance is 3 years
    • ·         Funding Level 2:
    • ·         Maximum funding of $750,000 for direct costs (plus indirect costs)
    • ·         Maximum period of performance is 3 years
    • ·         Funding Level 2 – Partnering PI Option:
    • ·         Maximum funding of $1M for direct costs (plus indirect costs)
    • ·         Maximum period of performance is 3 years

     

    Breakthrough Award Level 3 & 4– Preproposal May 15, 2018

    • ·         Independent investigators at all academic levels (or equivalent) are eligible.
    • ·         Each investigator may submit one Funding Level 3 pre-application and on Funding Level 4 pre-application as a PI or Initiating PI.
    • ·         Supports promising research that has the potential to lead to or make breakthroughs in breast cancer.
    • ·         Potential impact of the research may be near-terms or long-term, but it must be significant and go beyond an incremental advancement.
    • ·         Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application.
    • ·         It is the responsibility of the PI to select the funding level that is most appropriate for the research proposed.  The funding level should be selected based on the scope of the research project, rather than the amount of the budget.
    • ·         Clinical trials are allowed.
    • ·         There are no limitations on the number of applications for which an investigator may be named as a Partnering PI.  However, applicants are discouraged from submitting as a Partnering PI on multiple applications unless they are clearly unique, meaningful collaborations addressing distinct research questions.
    • ·         PIs must include two or more breast cancer advocates on their research team.
    • ·         Submission of a preproposal is required; application submission is by invitation only.

    Funding Level 3:

    Maximum funding of $2.5M in direct costs (plus indirect costs)

    Maximum period of performance is 4 years

    Funding Level 3 – Partnering PI Option:

    Maximum funding of $4M for direct costs (plus indirect costs)

    Maximum period of performance is 4 years

    Funding Level 4 and Funding Level 4 – Partnering PI Option:

    Maximum funding of $10M for direct costs (plus indirect costs)

    Maximum period of performance is 4 years

     

    Breakthrough Fellowship Award – Letter of Intent due May 16, 2018

    As of the application submission deadline, all eligible PIs must have:

    ·         Successfully completed the requirements for a doctoral or medical degree, and

    ·         Been in the laboratory or clinical research setting in which the proposed research is to be performed for no more than 2 years, and

    ·         A total of less than 4 years’ experience in a postdoctoral fellowship or mentored clinical research training program (excludes any clinical residency or fellowship training)

    Mentor

    Must have breast cancer research experience, including current funding and recent publications

    ·         Supports exceptionally talented, “best and brightest” recent doctoral or medical graduates in pursuit of promising research that has the potential to lead to or make breakthroughs in breast cancer.

    ·         Potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement.

    ·         Individualized researcher development plan and mentorship should prepare the PI for an independent career at the forefront of breast cancer research or patient care.

    ·         The PI is not required to have previous experience in breast cancer research.

    ·         Maximum funding of $300,000 for direct costs (plus indirect costs)

    • ·         Maximum period of performance is 3 years

     

    Era of Hope Scholar Award – Letter of Intent due May 16, 2018

    Independent, non-mentored investigators within 6 years of their last training position (e.g., postdoctoral fellowship, medical residency, clinical fellowship) as of the application submission deadline

    ·         Submission of a Letter of Intent is required prior to full application submission.

    ·         Supports exceptionally talented, creative early-career scientists who have demonstrated that they are the “best and brightest” in their fields.

    ·         PIs should articulate a vision that challenges current dogma and demonstrates an ability to look beyond tradition and convention.

    ·         PIs must exhibit strong potential for leadership in breast cancer.

    ·         Experience in breast cancer research is not required; however, the application must focus on breast cancer, and the PI must maintain a 50% dedication of his/her full-time professional effort during the award period to breast cancer research.

    • ·         PIs are required to include breast cancer advocates on their research team.
    • ·         Preliminary data are allowed, but not required.

    ·         Maximum funding of $2.5M for direct costs (plus indirect costs)

    • ·         Maximum period of performance is 4 years

     

    Innovator Award – Preproposal due May 15, 2018

    Associate Professor or above (or equivalent).

    ·         Supports visionary individuals who have demonstrated creativity, innovative work, and leadership in any field.

    ·         Provides opportunity to pursue novel, visionary, high-risk ideas that will accelerate progress toward ending breast cancer.

    ·         PIs must include two or more breast cancer advocates on their research team.

    • ·         Preproposal is required; application submission is by invitation only.

    ·         Maximum funding of $5M for direct costs (plus indirect costs).

    • ·         Maximum period of performance is 4 years

     

     

    Distinguished Investigator Award – Preproposal due May 15, 2018

    Assistant Professor or above (or equivalent) and more than 6 years beyond the PI’s last training position as of the application submission deadline

    ·         Supports established visionary leaders from any field to pursue innovative ideas that could accelerate progress toward ending breast cancer.

    ·         The PI must propose research that is a fundamental shift from his/her track record of research.

    ·         Does not support continuation of or minor advancement from the PI’s published line of research.

    ·         If the PI is not an established breast cancer researcher, he/she must clearly articulate a motivation and commitment for proposing a conceptual shift in his/her research and must include at least one collaborator with breast cancer expertise.

    ·         PIs must include two or more breast cancer advocates on their research team.

    ·         High-risk/high-reward projects pursuing innovative new paradigms are encouraged, but not required.

    • ·         Preproposal is required; application submission is by invitation only.

    ·         Maximum funding of $3M for direct costs (plus indirect costs)

    • ·         Maximum period of performance is 4 years

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism is also found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the BCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

     

    Point of Contact:

    CDMRP Help Desk
    301-682-5507
    help@eBrap.org



1717 K ST NW Suite 900

Washington, DC 20006

202-951-7701  |  admin@navref.org

Powered by Wild Apricot Membership Software